Arv­inas has inked an­oth­er Big Phar­ma part­ner­ship to get their pro­tein degra­da­tion en­gines revving — for both hu­mans and crops.

All told, the Ger­man con­glom­er­ate is wa­ger­ing $115 mil­lion on the po­ten­tial of Arv­inas’ tech plat­form, which us­es an E3 lig­ase to tag tar­get pro­teins with an ubiq­ui­tin, flush­ing these dis­ease cul­prits down the cell’s nat­ur­al “garbage dis­pos­al.” And Bay­er is in for the whole pack­age, with a col­lab­o­ra­tion, an eq­ui­ty in­vest­ment and a joint ven­ture in play.

A har­bin­ger of the pro­tein degra­da­tion space, Arv­inas comes of age as peers at C4 Ther­a­peu­tics and Kymera al­so gains pop­u­lar­i­ty among the likes of Bio­gen, Ver­tex and Glax­o­SmithK­line. Com­pared to the tra­di­tion­al in­hi­bi­tion ap­proach, get­ting rid of prob­lem­at­ic pro­teins promis­es to be a much more durable so­lu­tion for dis­eases like can­cer.

Jo­erg Moeller Linkedin

“Be­cause PRO­TACs don’t in­hib­it the tar­get pro­tein’s en­zy­mat­ic ac­tiv­i­ty, but bind their tar­gets with high se­lec­tiv­i­ty, it may be pos­si­ble to re­tool pre­vi­ous­ly in­ef­fec­tive in­hibitor mol­e­cules as PRO­TACs for next-gen­er­a­tion med­i­cines for pa­tients,” Jo­erg Moeller, Bay­er’s head of R&D, said in a state­ment.

On the ther­a­peu­tic side, Bay­er’s to­tal com­mit­ment — up­front, R&D sup­port plus eq­ui­ty — amounts to $60 mil­lion. It gets them the rights to nov­el lead struc­tures Arv­inas gen­er­ates in the process but doesn’t cov­er the ad­di­tion­al $685 mil­lion in po­ten­tial mile­stone pay­ments.

The pact will span car­dio­vas­cu­lar, on­co­log­i­cal and gy­ne­co­log­i­cal dis­eases.

The oth­er $55 mil­lion in the deal goes, in the course of six years, to a joint ven­ture set up to ex­plore how Arv­inas’ tech­nol­o­gy can tack­le the weeds, in­sects or dis­eases en­dem­ic in agri­cul­ture. Where pre­vi­ous crop pro­tec­tion ef­forts have suc­cumbed to re­sis­tance, pro­tein degra­da­tion may be able to re­vive them, the part­ners said.

John Hous­ton Arv­inas

“As the first com­pa­ny found­ed to ex­plore tar­get­ed pro­tein degra­da­tion, we’ve been ex­cit­ed about the po­ten­tial to im­prove the lives of pa­tients since our in­cep­tion,” said Arv­inas CEO John Hous­ton. “This col­lab­o­ra­tion en­ables us not on­ly to ex­pand our plat­form in­to new ther­a­peu­tic ar­eas, but al­so be­gins a new jour­ney in ap­ply­ing our ap­proach to agri­cul­ture.”

The cash ex­changed trumps pre­vi­ous part­ner­ships, in which Genen­tech and Pfiz­er paid less to get dis­cov­ery al­liances start­ed but pledged biobucks, great­ly rais­ing Arv­inas’ pro­file be­fore it even got in­to the clin­ic. Its lead ther­a­py in prostate can­cer is now in Phase I tri­als.

Im­age: Shut­ter­stock

The FDA has been insisting for months that a Covid-19 vaccine had to be at least 50% effective – a measure of transparency meant to shore public trust in the agency and in a vaccine that had been brought forward at record speed and record political pressure. But now, with concerns of a Trump-driven authorization arriving before the election, the agency may be raising the bar.

The FDA is set to release new guidance that would raise safety and efficacy requirements for a vaccine EUA above earlier guidance and above the criteria used for convalescent plasma or hydroxychloroquine, The Washington Post reported. Experts say this significantly lowers the odds of an approval before the election on November 3, which Trump has promised despite vocal concerns from public health officials.

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Over a decade after launch, Blueprint Medicines nabbed the first approval for their first drug earlier this year. Now, as they move forward with a Roche-partnered global launch, they’re touting data that could push them into more patients.

The Jeff Albers-led Cambridge biotech released their full pivotal data for Ayvakit in patients with advanced systemic mastocytosis. In one 53-person study, they showed that 76% of patients responded to the drug, 36% had complete responses and that on average their responses lasted for just over 3 years. A smaller, 32-patient study had a 75% response rate and most were still responding after 10.4 months, the last follow-up.

President Donald Trump, who seems intent on announcing a Covid-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

Having worked in parallel for years to move their respective PD-1 inhibitors up to the first-line treatment of gastrointestinal cancers, Merck and Bristol Myers Squibb finally have the data at ESMO for a showdown.

Comparing KEYNOTE-590 and CheckMate-649, of course, comes with the usual caveats. But a side-by-side look at the overall survival numbers also offer some perspective on a new frontier for the reigning checkpoint rivals, both of whom are claiming to have achieved a first.